IMP-1088

Add links
Source: Wikipedia, the free encyclopedia.
IMP-1088
Names
Preferred IUPAC name
1-(5-{3,4-Difluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl}-1-methyl-1H-indazol-3-yl)-N,N-dimethylmethanamine
Identifiers
3D model (
JSmol
)
  • Key: SOXNKJCQBRQUMS-UHFFFAOYSA-N
  • CC1=NN(C)C(=C1CCOC2=C(C=CC(=C2F)F)C3=CC=C4C(=C3)C(=NN4C)CN(C)C)C
Properties
C25H29F2N5O
Molar mass 453.538 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

IMP-1088 is an

NMT2 capable of preventing rhinoviral replication,[1] an area of research relating to potential treatment of the common cold. IMP-1088 works to keep cells from generating infectious virus by targeting the cell instead of the rhinovirus itself. It does this by blocking the NMT protein of the host cell which prevents the virus from assembling its capsid, since viral capsid myristoylation by host NMT is essential for assembly. It is thought unlikely that viruses will evolve resistance to such an approach since IMP-1088 works against the human cell and not the virus.[2][3]

References

  1. PMID 29760414
    .
  2. ^ Borman, Stu. "Agent stops common cold virus replication". Chemical & Engineering News. Retrieved 20 May 2018.
  3. ^ Houser, Kristin (19 May 2018). "A team of researchers may have actually found a cure to the common cold". Business Insider. Retrieved 20 May 2018.
Retrieved from "https://en.wikipedia.org/w/index.php?title=IMP-1088&oldid=1148477618"